Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.
Pharmacoepidemiol Drug Saf. 2024 Feb;33(2):e5752. doi: 10.1002/pds.5752.
To describe the prescribing trends of proton pump inhibitors (PPIs) and H receptor antagonists (H RAs) among children with gastroesophageal reflux in the United Kingdom between 1998 and 2019.
We conducted a population-based retrospective cohort study using data from the Clinical Practice Research Datalink that included all children aged ≤18 years with a first ever diagnosis of gastroesophageal reflux between 1998 and 2019. Using negative binomial regression, we estimated crude and adjusted annual prescription rates per 1000 person-years and corresponding 95% confidence intervals (CIs) for PPIs and H RAs. We also assessed rate ratios of PPIs and H RAs prescription rates to examine changes in prescribing over time.
Our cohort included 177 477 children with a first ever diagnosis of gastroesophageal reflux during the study period. The median age was 13 years (IQR: 1, 17) among children prescribed PPIs and 0.2 years (IQR: 0.1, 0.6) among those prescribed H RAs. The total prescription rate of all GERD drugs was 1468 prescriptions per 1000 person-years (PYs) (95% CI 1463-1472). Overall, PPIs had a higher prescription rate (815 per 1000 PYs, 95% CI 812-818) than H RAs (653 per 1000 PYs 95% CI 650-655). Sex- and age-adjusted rate ratios of 2019 versus 1998 demonstrated a 10% increase and a 76% decrease in the prescription rates of PPIs and H RAs, respectively.
Prescription rates for PPIs increased, especially during the first half of the study period, while prescription rates for H RA decreased over time.
描述 1998 年至 2019 年间英国儿童胃食管反流病质子泵抑制剂(PPIs)和 H2 受体拮抗剂(H RAs)的处方趋势。
我们使用临床实践研究数据链接中的数据进行了一项基于人群的回顾性队列研究,该研究纳入了 1998 年至 2019 年间首次诊断为胃食管反流病的所有年龄≤18 岁的儿童。我们使用负二项回归估计了 PPI 和 H RA 的每 1000 人年的粗处方率和调整后的处方率,以及相应的 95%置信区间(CI)。我们还评估了 PPI 和 H RA 处方率的比率比值,以检查随时间的处方变化。
我们的队列包括 177477 名在研究期间首次诊断为胃食管反流病的儿童。在接受 PPI 治疗的儿童中,中位年龄为 13 岁(IQR:1,17),在接受 H RA 治疗的儿童中,中位年龄为 0.2 岁(IQR:0.1,0.6)。所有 GERD 药物的总处方率为 1468 张/1000 人年(95%CI 1463-1472)。总体而言,PPI 的处方率(815 张/1000 人年,95%CI 812-818)高于 H RA(653 张/1000 人年,95%CI 650-655)。2019 年与 1998 年相比,男女和年龄调整后的比率比值显示,PPI 和 H RA 的处方率分别增加了 10%和减少了 76%。
PPI 的处方率增加,特别是在研究的前半段,而 H RA 的处方率随着时间的推移而下降。